Dec 12 (Reuters) – The European Medicines Agency has recommended the approval of GSK’s add-on drug to treat asthma and a chronic inflammatory sinus condition, the company said on Friday.
The drug, chemically known as depemokimab, received a positive opinion from the EMA’s Committee for Medicinal Products for Human Use.
The panel’s opinion was based on data from two late-stage studies that showed sustained efficacy with a twice-yearly dosing regimen for depemokimab.
The European Commission decision on approval for the drug is expected in the first quarter of 2026.
(Reporting by Sneha S K in Bengaluru; Editing by Shailesh Kuber)
Comments